© 2023 MJH Life Sciences™ and Nutritional Outlook. All rights reserved.
The patent demonstrates the synergistic effects of thymoquinone and omega-3 fatty acids for healthy inflammatory responses.
TriNutra (Harrison, NY) has announced the approval of a US patent (no. 11,426,365) protecting its ThymoQuin ingredient. The patent demonstrates the synergistic effects of thymoquinone and omega-3 fatty acids for healthy inflammatory responses. ThymoQuin contains thymoquinone from black seed oil and other sources, as well as omega-3 in different forms, such as various mixtures of EPA and DHA in at least a 1:7 ratio.
The patent claim states, ““the patented composition contains the two actives at just the right relative amounts to maximize its beneficial anti-inflammatory effects.” For example, a preclinical study found that the combination supports obesity-induced inflammation, oxidative stress, and insulin resistance in mice.
“We are thrilled to announce the approval of our patent which shows strong support to raise awareness of the many benefits of black seed oil, and now, this further demonstrates its powerful synergistic impacts,” said Morris Zelkha, CEO of TriNutra, in a press release. “Additional research has shown that ThymoQuin, although effective on its own, can also potentiate the impact of other well-known ingredients such as astaxanthin, hemp oil, lutein, beta-carotene and vitamin D.”